Obesity

• The effect of semaglutide therapy on hepatic fat content and on the acute response of liver fat to high-fat load Pending
  2023-504988-16-00 5
• A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of … Pending
  2024-519296-25-00 3 "Healthy volunteers"
• A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants with Type 2 Diabetes Mellitus(T2DM … Pending
  2025-521401-41-00 3 "Type 2 Diabetes Mellitus (T2DM) and overweight or obesity"
• Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascu … Pending
  2025-522486-29-01 5 "Diabetes Mellitus"
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending
  2025-523486-17-00 5
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending
  2025-523510-87-00 5
• Efficacy and Safety of KAI-9531 compared with Semaglutide in Participants Living With Obesity Who Do Not Have Diabetes Pending
  2025-523511-11-00 5
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 "Obesity or Overweight and Type 2 Diabetes"
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 "Obesity or Overweight Without Type 2 Diabetes"
• Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives Recruiting
  2025-524052-58-00 3 2026-05-21 "Healthy Overweight or Obese"
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08
• Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting
  2025-523974-18-00 5 2026-04-30
• A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of … Recruiting
  2025-524856-73-00 3 2026-03-13 "Not Applicable"
• A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO779508 … Recruiting
  2024-519277-18-00 3 2025-05-08 "Obesity or Overweight"
• A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-1389 Recruiting
  2024-514853-31-00 1 2024-09-10 "Obesity / Right heart failure (healthy participants)"
• FIT-HF - Effect of weight loss on physical and cardiac performance in patients with heart failure and obesity Recruiting
  2023-503753-35-01 4 2024-03-20 "Obesity and Heart Failure with reduced Ejection Fracition"
• OBEVIDOS “Treatment of vitamin D deficit in obese children and adolescents: an open label randomized controlled study comparing the efficacy … Recruiting
  2023-507089-18-00 5 2023-11-24 "Obese children and adolescents"
• A Trial to Study the Safety and Efficacy of a New Drug Combination for Weight Loss While Maintaining Muscles Recruitment ended
  2024-519561-22-00 4 2025-07-07
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT … Recruitment ended
  2024-515523-11-00 5 2025-06-09 "Chronic Weight Management"
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA … Recruitment ended
  2024-515524-36-00 5 2025-05-30 "Chronic Weight Management"
• A research study to look into the long-term effect on weight loss of CagriSema in people with obesity Recruitment ended
  2024-512144-39-00 5 2025-01-22
• DUTCH-WAIST Recruitment ended
  2022-501392-81-00 6 2024-07-25
• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Recruitment ended
  2022-502442-27-00 5 2024-01-08
• A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokine … Recruitment ended
  2023-504215-32-00 9 2023-09-28 "Overweight and obesity"

Showing 1–24 of 52 trials